Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ther Clin Risk Manag. 2008 Feb;4(1):99-107.

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.

Author information

  • 1Pain Center, McGill University Health Center Montréal, Quebec, Canada.

Abstract

Chemotherapy-induced nausea and vomiting (CINV) in cancer patients places a significant burden on patients' function and quality of life, their families and caregivers, and healthcare providers. Despite the advances in preventing CINV, a substantial proportion of patients experience persistent nausea and vomiting. Nabilone, a cannabinoid, recently received Food and Drug Administration approval for the treatment of the nausea and vomiting in patients receiving cancer chemotherapy who fail to achieve adequate relief from conventional treatments. The cannabinoids exert antiemetic effects via agonism of cannabinoid receptors (CB1 and CB2). Clinical trials have demonstrated the benefits of nabilone in cancer chemotherapy patients. Use of the agent is optimized with judicious dosing and selection of patients.

KEYWORDS:

chemotherapy-induced nausea/vomiting; nabilone; pain

PMID:
18728826
[PubMed]
PMCID:
PMC2503671
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk